Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -559,599 | -811,011 | -92,541 | 560,120 | 369,005 |
| Depreciation Amortization | 517,128 | 338,882 | 164,873 | 660,067 | 491,650 |
| Income taxes - deferred | -381,662 | -110,252 | -43,833 | -208,327 | -205,972 |
| Accounts receivable | -40,466 | 10,530 | 66,049 | -21,115 | -21,979 |
| Accounts payable and accrued liabilities | 68,823 | 6,465 | 19,131 | -20,073 | -16,938 |
| Other Working Capital | 91,638 | -39,212 | 287,904 | -76,720 | 3,212 |
| Other Operating Activity | 1,297,393 | 1,123,237 | 28,201 | 501,956 | 378,350 |
| Operating Cash Flow | $993,255 | $518,639 | $429,784 | $1,395,908 | $997,328 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -140,175 | 99,950 | -130,050 | -460,125 | -280,125 |
| PPE Investments | -900,076 | -26,848 | -13,881 | -38,070 | -24,783 |
| Net Acquisitions | N/A | -858,053 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -97,500 | -25,000 | -25,000 | -10,000 | -10,000 |
| Other Investing Activity | -97,500 | -25,000 | -25,000 | -10,000 | -10,000 |
| Investing Cash Flow | $-1,137,751 | $-809,951 | $-168,931 | $-508,195 | $-314,908 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 980,767 | 980,767 |
| Debt Repayment | -773,250 | -765,500 | -757,750 | -606,000 | -598,250 |
| Common Stock Issued | 22,677 | 21,944 | 11,447 | 20,647 | 11,451 |
| Common Stock Repurchased | -125,023 | -125,023 | N/A | -311,429 | -311,429 |
| Other Financing Activity | -73,224 | -69,412 | -67,163 | -63,469 | -53,748 |
| Financing Cash Flow | $-948,820 | $-937,991 | $-813,466 | $20,516 | $28,791 |
| Exchange Rate Effect | 6,522 | 6,319 | 1,695 | -1,675 | 614 |
| Beginning Cash Position | 2,412,864 | 2,412,864 | 2,412,864 | 1,506,310 | 1,506,310 |
| End Cash Position | 1,326,070 | 1,189,880 | 1,861,946 | 2,412,864 | 2,218,135 |
| Net Cash Flow | $-1,086,794 | $-1,222,984 | $-550,918 | $906,554 | $711,825 |
| Free Cash Flow | |||||
| Operating Cash Flow | 993,255 | 518,639 | 429,784 | 1,395,908 | 997,328 |
| Capital Expenditure | -900,076 | -26,848 | -13,881 | -38,070 | -24,783 |
| Free Cash Flow | 93,179 | 491,791 | 415,903 | 1,357,838 | 972,545 |